The Achievements and Challenges of Mesenchymal Stem Cell-Based Therapy in Inflammatory Bowel Disease and Its Associated Colorectal Cancer

<div>The percentage distribution of MSC-based clinical trials on some selected conditions. Some of the most registered MSC-based clinical trials include neurological diseases (17%), cardiovascular diseases (13%), bone diseases, and diabetes (7% each). IBD contributes approximately 3% to MSC-based clinical trials.</div>

Stem Cells International

fig4

Figure 4

Figure 4: The Achievements and Challenges of Mesenchymal Stem Cell-Based Therapy in Inflammatory Bowel Disease and Its Associated Colorectal Cancer 